Protagonist Therapeutics, IncPTGX
Market cap
$5.3B
P/E ratio
| Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| License and collaboration revenue | - | - | 31 | - | - | 27 | 27 | 60 | 434 |
| Research and development | 26 | 46 | 59 | 65 | 75 | 126 | 126 | 120 | 138 |
| General and administrative | 7 | 12 | 14 | 16 | 19 | 27 | 32 | 33 | 43 |
| Total operating expenses | 33 | 58 | 73 | 81 | 93 | 153 | 158 | 154 | 182 |
| Income (loss) from operations | -33 | -38 | -42 | -81 | -65 | -126 | -131 | -94 | 253 |
| Interest income | 0 | 1 | 3 | 3 | 1 | 0 | 4 | 15 | 26 |
| Other income (expense), net | -0 | - | - | -0 | -0 | -0 | -0 | -0 | 0 |
| Income (loss) before income tax expense | - | - | -40 | -78 | -65 | -126 | -127 | - | 279 |
| Income tax expense | - | - | 1 | -1 | 1 | - | - | - | 4 |
| Net Income (Loss) | -37 | -37 | -39 | -77 | -66 | -126 | -127 | -79 | 275 |
| Earnings Per Share, Basic | - | - | - | - | - | - | -2.6 | -1.39 | 4.47 |
| Earnings Per Share, Diluted | - | - | - | - | - | - | -2.6 | -1.39 | 4.23 |